Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

首页> 外文期刊>Nature immunology >Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

【24h】

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

机译：超出PD-1，PD-L1和CTLA-4之外的抑制受体和配体：突破或备用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-L1 have made substantial clinical progress in cancer, a considerable proportion of patients remain unresponsive to treatment. Targeting novel IR-ligand pathways in combination with current immunotherapies may improve clinical outcomes. New clinical immunotherapeutics target T cell-expressed IRs (LAG-3, TIM-3 and TIGIT) as well as inhibitory ligands in the B7 family (B7-H3, B7-H4 and B7-H5), although many of these targets have complex biologies and unclear mechanisms of action. With only modest clinical success in targeting these IRs, current immunotherapeutic design may not be optimal. This Review covers the biology of targeting novel IR-ligand pathways and the current clinical status of their immunotherapeutics, either as monotherapy or in combination with antibody to PD-1 or to its ligand PD-L1. Further understanding of the basic biology of these targets is imperative to the development of effective cancer immunotherapies.

机译：虽然靶向抑制受体（IRS）CTLA-4，PD-1或PD-L1的免疫治疗剂在癌症中进行了实质性临床进展，但相当大比例的患者对治疗仍未响应。靶向新型IR-LIGAND途径与电流免疫疗法的组合可以改善临床结果。新的临床免疫治疗靶T细胞表达的IRS（LAG-3，TIM-3和TIGIT）以及B7家族中的抑制配体（B7-H3，B7-H4和B7-H5），虽然这些靶中的许多靶标具有复杂的生物学和不明确的作用机制。只有适度的临床成功瞄准这些IRS，目前的免疫治疗设计可能不是最佳的。本综述涵盖了靶向新型IR-LigAnd途径的生物学和免疫治疗剂的当前临床状态，也可以作为单药治疗或与PD-1或其配体PD-L1的抗体组合。进一步了解这些目标的基本生物学对有效癌症免疫治疗的发展是必不可少的。

著录项

来源
《Nature immunology》 |2019年第11期|共10页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J] . Nature immunology . 2019,第11期

机译：超出PD-1，PD-L1和CTLA-4之外的抑制受体和配体：突破或备用
2. The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune Pathology [J] . Carla Claser, Eleanor M. Riley, Georges Emile Grau, PLoS Pathogens . 2012,第2期

机译：CTLA-4和PD-1 / PD-L1抑制途径独立调节宿主对疟原虫诱导的急性免疫病理的抵抗力
3. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1) [J] . Wen Biyan, Zhao Lin, Wang Yuchu, Preparative biochemistry & biotechnology: An international journal for rapid communication . 2020,第1a5期

机译：靶向编程死亡受体1（PD-1）/ PD-1配体1的相互作用界面（PD-1 / PD-L1）
4. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019

机译：免疫检查点的分子动力学程序性细胞死亡蛋白I，PD-1：配体PD-L1与单克隆抗体nivolumab结合后BC环的构象变化
5. Characterizing the roles of the PD-1 ligands, PD-L1 and PD-L2, in regulating the T cell response to influenza virus. [D] . Brown, Keturah Elise. 2010

机译：表征PD-1配体PD-L1和PD-L2在调节T细胞对流感病毒的反应中的作用。
6. Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population [O] . Yuan Ma, Xiuchun Liu, Jingyan Zhu, 2015

机译：共抑制分子（CTLA-4 / PD-1 / PD-L1）的多态性与中国人群非小细胞肺癌的风险
7. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways [O] . Yunlong Zhao, Calvin K. Lee, Chia-Hao Lin, 2019

机译：PD-L1：CD80 CIS-异二聚体触发共刺激受体CD28，同时压制抑制性PD-1和CTLA-4途径

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

摘要

著录项

相似文献

相关主题

期刊订阅